多巴丝肼联合左旋多巴治疗帕金森病的效果及对血清炎症因子的影响

Effect of Levodopa and Benserazide Hydrochloride Combined with Levodopa in the Treatment of Parkinson Disease and Its Effect on Serum Inflammatory Factors

目的:研究多巴丝肼联合左旋多巴治疗帕金森病的效果及对患者血清炎症因子的影响。方法:选择2019年1月-2021年12月山东省泰安荣军医院收治的74例帕金森病患者作为研究对象,采用随机数字表法分为观察组(n=37)、对照组(n=37)。对照组采用多巴丝肼治疗,观察组采用多巴丝肼联合左旋多巴治疗。比较两组总有效率、不良反应发生率、炎症因子水平及生活质量评分。结果:观察组总有效率高于对照组,差异有统计学意义(P<0.05);治疗后观察组肿瘤坏死因子-α(TNF-α)、白介素-6(IL-6)、白介素-1β(IL-1β)水平均低于对照组,差异均有统计学意义(P<0.05);治疗后观察组帕金森患者生活质量问卷(PDQ-39)中各维度评分与总分均低于对照组,差异均有统计学意义(P<0.05);观察组不良反应发生率低于对照组,差异有统计学意义(P<0.05)。结论:多巴丝肼联合左旋多巴治疗帕金森病效果显著,可有效控制炎症反应,改善患者生活质量,降低不良反应发生率,值得临床推广。

Objective: To study the effect of Levodopa and Benserazide Hydrochloride combined with Levodopa in the treatment of Parkinson disease and its effect on serum inflammatory factors in patients. Method: A total of 74 patients with Parkinson disease who were admitted to Taian Disabled Soldiers’ Hospital of Shandong Province from January 2019 to December 2021 were selected as the research subjects and divided into an observation group(n=37) and a control group(n=37) according to the random number table method. The control group was treated with Levodopa and Benserazide Hydrochloride, and the observation group was treated with Levodopa and Benserazide Hydrochloride combined with Levodopa. The total effective rate, incidence of adverse reactions, levels of inflammatory factors and quality of life scores were compared between the two groups. Result: The total effective rate of the observation group was higher than that of the control group, the difference was statistically significant(P<0.05).After treatment, the levels of tumor necrosis factor-α(TNF-α), interleukin-6(IL-6) and interleukin-1β(IL-1β) in the observation group were lower than those in the control group, the differences were statistically significant(P<0.05). After treatment, scores of each dimension and total scores in Parkinson disease quality of life questionnaire(PDQ-39) in the observation group were lower than those in the control group, the differences were statistically significant(P<0.05). The incidence of adverse reactions in the observation group was lower than that in the control group, the difference was statistically significant(P<0.05). Conclusion: Levodopa and Benserazide Hydrochloride combined with Levodopa in the treatment of parkinson disease has significant effect, can effectively control the inflammatory response, improve the quality of life of patients, and reduce the incidence of adverse reactions, which is worthy of clinical promotion.